Source: InvestorPlace
Five Prime Therapeutics (FPRX) stock is soaring higher on Thursday following news that Amgen (AMGN) is acquiring the company.
Five Prime Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Five Prime Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – FPRX
Source: Business Wire
NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) to Amgen Inc. for $38.00 per share in cash is fair to Five Prime shareholders. Halper Sadeh encourages Five Prime shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns wheth
STAT+: Amgen spends $1.9 billion on Five Prime, eyeing an expansion in Asia
Source: STAT News
Amgen said it will purchase Five Prime Therapeutics for $1.9 billion to obtain a potential treatment for gastric cancer, a move that will also expand the biotech giant’s focus in…
Amgen snaps up cancer drug player Five Prime, adding PhIII-ready FGFR2b drug in $2B M&A play
Source: Endpoints News
Amgen is making a long-awaited move on the M&A side, buying South San Francisco-based Five Prime $FPRX for close to $2 billion and adding a slate of new cancer drugs to the pipeline. Amgen is paying $38 a share, putting the deal value at $1.9 billion. The stock closed at
Amgen To Acquire Five Prime Therapeutics For $1.9 Billion in Cash
Source: PR Newswire
/PRNewswire/ — Amgen (NASDAQ: AMGN) and Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology…
Amgen Announces 2021 Second Quarter Dividend
Source: PR Newswire
THOUSAND OAKS, Calif., March 3, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the second quarter of 2021. The dividend will be paid on June 8, 2021, to all stockholders of record as of the close of business on…
Blood Cancer Drugs Market With Key Players like Johnson & Johnson, Amgen, Bayer AG., Pfizer, AbbVie Inc., Roche Holding AG., Celgene Corporation, AstraZeneca, Novartis AG, GlaxoSmithKline PLC
Source: OpenPR
An off-the-shelf report on Blood Cancer Drugs Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Source: PR Newswire
THOUSAND OAKS, Calif., March 2, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO® (blinatumomab) compared with consolidation chemotherapy before allogeneic…
Cell and Gene Therapy Market – Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals
Source: OpenPR
Cell and Gene Therapy Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu,
Global Peptide Therapeutics Market (2021 to 2026) – Growth, Trends, COVID-19 Impact, and Forecasts – ResearchAndMarkets.com
Source: Business Wire
DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering. The Peptide Therapeutics Market is valued at approximately USD 28,510.60 million in 2020 and is expected to witness a revenue of USD 51,360.30 million in 2026, with a CAGR of 9.66% over the forecast period (2021-2026). Companies Mentioned Eli Lilly and Company Amgen, Inc. Pfizer, Inc. Bristol-Myers Squibb Company Sa
